Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an fc fusion protein
The trial randomised adults with obesity who have achieved 5% WL by the end of the 12-week lead-in period (mean WL at the lead-in period was 6.9%) to placebo or tirzepatide
Phase II SToMP-AD To rigorously test D+Q in the context of AD, we have initiated a Phase II multi-site, randomized, doubleblind placebo-controlled trial (Phase II SToMP-AD, NCT04685590)
You inject into the fatty tissue of your abdomen, thigh, or upper arm
Laboratory assays often measure these effects using: cyclic AMP reporter systems kinase phosphorylation analysis transcriptional profiling These approaches help researchers examine how multi-receptor signaling alters intracellular signaling dynamics
This is not medical advice, it is just my story